You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新華製藥H股曾倍升至10元紀錄高 A股連續兩天漲停 成爲在研新冠口服藥阿茲夫定生產和經銷商
新華製藥(00719.HK)(000756.SZ)與真實生物簽署《戰略合作協議》,真實生物同意公司爲其擁有的阿茲夫定等產品,在中國及經雙方同意的其他國家的產品生產商和經銷商。 阿茲夫定是用於治療艾滋病的藥品,也是目前內地多款在研新冠口服藥之一。新華製藥H股今早曾飆升1.3倍至10元,創上市新高,現報6.55元,仍飆50%,一向薄弱成交急增至3,343萬股,爲多年來罕見;新華製藥A股連續第二天漲停報11.35元人民幣。 新華製藥上週公佈,首季未經審覈純利按年升8.2%至1.09億人民幣,總營收按年升3.6%至18.31億元人民幣。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account